Coherus Oncology, Inc.
CHRSNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $156.37M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.94$2.62
- Volume (live)
- -
- Avg. volume (3M)
- 1.53M
Coherus Oncology (CHRS) Stock Price & Financial Analysis
Coherus Oncology Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.98 - $1.02 |
|---|---|
| 52-Week High | $2.62 |
| 52-Week Low | $0.94 |
| Open | $1.01 |
| Volume (last close) | 686.79K |
| Average Volume (3M) | 1.53M |
| Revenue (TTM) | 50.94M |
|---|---|
| Net Income (TTM) | -122.76M |
| Free Cash Flow (TTM) | -186.03M |
| EPS (TTM) | −$0.93 |
| Profit Margin | -241.00% |
| Operating Margin | -311.56% |
| Return on Equity (ROE) | -201.78% |
| Debt to Equity | 0.61 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 156.37M |
|---|---|
| Shares Outstanding | 154.82M |
| Price to Sales (P/S) | 3.07 |
| Price to Book (P/B) | 2.57 |
| EV/EBITDA | -0.78 |
| 50-Day MA | $1.23 |
|---|---|
| 200-Day MA | $1.55 |
| 1-Year Change | −37.13% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Coherus Oncology at a Glance
As of the Oct 26, 2026 close, Coherus Oncology (CHRS) has a market capitalization of $156.37M. The stock trades at 3.1× sales. Over the trailing twelve months it lost $122.76M on revenue of $50.94M and burned $186.03M of free cash flow. Revenue fell 64.3% year over year.
As of its latest reported balance sheet, it holds $82.92M in cash and securities against $37.25M of debt, a net cash position of $45.68M.
Coherus Oncology does not currently pay a dividend.
The share price is down 37.1% over the past year. At $1.01 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $0.94 to $2.62, below its 200-day moving average of $1.55.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $7.75, 667.3% above the Oct 26, 2026 close.
Frequently Asked Questions About Coherus Oncology
What is the current stock price for CHRS?
As of the Oct 26, 2026 close, CHRS stock trades at $1.01. The 52-week range is $0.94–$2.62, with a day range of $0.98–$1.02.
What is the P/E ratio for CHRS?
The P/E ratio (Price-to-Earnings) for CHRS is shown in the Key Statistics section. This valuation metric helps compare Coherus Oncology, Inc. to industry peers.
Does CHRS pay dividends?
Coherus Oncology does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CHRS?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for CHRS is Buy. The average 12-month price target is $7.75, a 667.3% upside from the Oct 26, 2026 close of $1.01.
What is the market cap of CHRS?
As of the Oct 26, 2026 close, Coherus Oncology's market capitalization is $156.4M, classifying it as a micro-cap company. Coherus Oncology operates in the Healthcare sector within the Biotechnology industry.